DHA dFdC
Alternative Names: DHA-dFdC; DHA-gemcitabine - Dominari Holdings; Gem-DHA; Gemcitabine DHA conjugate - Dominari Holdings; Gemcitabine docosahexaenoic acid conjugate - Dominari HoldingsLatest Information Update: 28 Nov 2024
At a glance
- Originator University of Texas at Austin
- Developer Dominari Holdings; University of Texas at Austin
- Class Antineoplastics; Deoxyribonucleosides; Drug conjugates; Pyrimidine nucleosides; Small molecules; Unsaturated fatty acids
- Mechanism of Action Antioxidants; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (PO)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (IV, Injection)
- 03 Mar 2022 AIkido Pharma files for patent protection with the United States Patent and Trademark Office for DHA dFdC in USA